Herbridge, 18 May 2011_Huifeng Pharmaceutical Co., Ltd (Huifeng Pharma ) announced to gain the CoS Certificate on its API ingredient diosmin in May. The certificate with valid period of 5 years marked that Huifeng Pharmar was permittd to market its diosmin in EU. Please visit the offical website of EDQM to gain detail imformation.
Huifeng Pharma is one of the biggest producers of APIs and pharmaceutical intermediates in China. The company made investments in terms of raw materials, quality control and marketing to meet CoS requirements. Huifeng Pharma is to date the first and the only pharmaceutical company to gain CoS Certificate related to diosmin in China. Huifeng Pharma's gaining the Certificate means that manufacturers in 27 memeber countries can directly purchase and use its diosmin.
Huifeng Pharma also gained the DMF registration number for its diosmin and troxerutin. Moreover, Huifeng Pharma successfully passed several GMP inspections by State Food and Drug Administration and gained the SFDA certificate for its rutin and troxerutin.
Copyright: www.herbridge.com
- White Paper on Bone and Joint Health of Chinese Consumers 2020
- Yili Dairy launched high-protein yogurt, focusing on sport people
- Sinopharm Xingsha launched the Japan's Champion probiotics
- China has introduced its first policy to support the industrial hemp industry
- Beyond Meat became the first overseas Artificial Meat company to set up a factory in China
- Nongfu Spring's market value exceeded HK $370 billion on its first day
- German infant nutrition brand Amykon launched two probiotics in China
- The revenue of Besunyoung in the first half year is about 610 million yuan
- Jellly candy and powder included in the health food filing dosage form in China
- H&H Group net profit increased by 9% for the first half of year
